Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfram Brugger

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Transfusion|April 19, 2002
Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivoStefan Scheding, Markus Bergmann, Akihiro Shimosaka, et al.
Transplantation|March 30, 2002
Sustained remission of an extensive monoclonal, Epstein-Barr virus-associated diffuse large B cell lymphoma in a kidney-pancreas transplant recipientMarkus G Manz, Christoph Berger, Hans-Peter Horny, et al.
Cancer|August 3, 2021
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemiaRebecca B Klisovic, Wing H Leung, Wolfram Brugger, et al.
British Journal of Cancer|September 4, 2015
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancerAlexander Stein, Djordje Atanackovic, Bert Hildebrandt, et al.
Leukemia & Lymphoma|November 24, 2015
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBruce D Cheson, Wolfram Brugger, Gandhi Damaj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancerWolfram Brugger, Nadja Triller, Maria Blasinska-Morawiec, et al.
The Lancet. Oncology|May 25, 2010
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyFederico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, et al.
The New England Journal of Medicine|April 29, 2026
CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host DiseaseKaramjeet S Sandhu, Jessica Cheng, Patrick W Mellors, et al.
Cancer Research|June 3, 2006
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patientsJan Wierecky, Martin R Müller, Stefan Wirths, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR MutationsBarbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Transfusion|April 19, 2002
Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivoStefan Scheding, Markus Bergmann, Akihiro Shimosaka, et al.
Transplantation|March 30, 2002
Sustained remission of an extensive monoclonal, Epstein-Barr virus-associated diffuse large B cell lymphoma in a kidney-pancreas transplant recipientMarkus G Manz, Christoph Berger, Hans-Peter Horny, et al.
Cancer|August 3, 2021
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemiaRebecca B Klisovic, Wing H Leung, Wolfram Brugger, et al.
British Journal of Cancer|September 4, 2015
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancerAlexander Stein, Djordje Atanackovic, Bert Hildebrandt, et al.
Leukemia & Lymphoma|November 24, 2015
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBruce D Cheson, Wolfram Brugger, Gandhi Damaj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancerWolfram Brugger, Nadja Triller, Maria Blasinska-Morawiec, et al.
The Lancet. Oncology|May 25, 2010
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyFederico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, et al.
The New England Journal of Medicine|April 29, 2026
CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host DiseaseKaramjeet S Sandhu, Jessica Cheng, Patrick W Mellors, et al.
Cancer Research|June 3, 2006
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patientsJan Wierecky, Martin R Müller, Stefan Wirths, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR MutationsBarbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
Pageof 6